ChartRow logo
Data provided bySource: Twelve Data
TAK
$21.43+1.47%
as of close, Nov 13, 2026
☾ AH $21.43 +1.47%
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Stock · HealthcareJapanese Stock Market · 1.1% of EWJMSCI EAFE · 0.2% of EFAMSCI World · 0.06% of URTHMSCI ACWI · 0.05% of ACWI
PeersHLNTEVAZTSGSKSNYVTRS
Share this page

TAK — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in TAK be worth today? →
TAK returns: By year · By month · By week · Trailing

Price data

Price
$21.43
YTD price return
+37.46%
YTD total return
+37.46%
Market cap
67.5B
Enterprise value
91.3B
Shares outstanding
3.2B
52W low
$13.91
52W high
$21.73
From 52W high
-1.38%
From 52W low
+54.06%
52W range
96%$13.91–$21.73
Beta
-0.08

Volume

Rel volume
1.23×
30D volume
3M
30D $ vol
60.9M

Insider trading

Insider net 1W
none
Insider net 1M
−$2.1M
Insider net 3M
−$5.5M
Insider net 1Y
−$15.2M

Form 4 transactions by trade date, as filed; latest on file 2026-11-04.

Fundamentals

Sales (ttm)
29.8B
Sales/share
$9.45
EPS (ttm)
-$0.32
Book value/share
$14.86
Net margin
-3.38%
ROE
-2.15%
ROA
-1.03%
Debt / equity
0.59×
Current ratio
1.09

Growth (CAGR, ttm) · 10Y

Sales
-0.87%+0.04%-0.25%n/a
FCF
+50.28%-14.22%+2.39%n/a
Shares
-1.00%-0.15%-0.02%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+0.13%+0.20%-0.23%n/a
FCF/share
+49.48%-14.38%+1.96%n/a
Book value/share
+2.24%-0.58%+0.05%n/a
Dividend/share
+4.99%+0.12%-5.04%n/a
Price
+50.53%+16.25%+8.24%-0.18%
Total return
+50.53%+18.83%+10.74%+3.06%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-67.0×
Fwd P/E
40.4×
P/S (ttm)
2.3×
P/B (mrq)
1.4×
EV/EBITDA (fy)
19.0×
EV/Sales (ttm)
3.1×
Buyback yield (cash, ttm)
0.49%
Shareholder yield (cash, ttm)
3.55%

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data
1D
+1.47%
5D
+1.95%
1M
+15.71%
3M
+23.23%
YTD
+37.46%
1Y
+50.49%
5Y
+48.61%
1D
+1.47%
5D
+1.95%
1M
+15.71%
3M
+23.23%
YTD
+37.46%
1Y
+50.49%
5Y
+66.55%

Fundamentals#

Revenue

5Y CAGR −0.3%5Y CAGR −0.3%
$29.8B FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

No quarters filed for this figure.

Operating income

5Y CAGR −61.4%5Y CAGR −61.4%
$41.1M FY26
FY18FY19FY20FY21FY22FY23FY24FY25FY26

No quarters filed for this figure.

EPS (diluted)

5Y n/m5Y n/m
−$0.32 FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

No quarters filed for this figure.

Free cash flow

5Y CAGR +2.4%5Y CAGR +2.4%
— FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

FY26: operating cash flow $6.9B, capex —

No quarters filed for this figure.

Shares (diluted)

5Y +0.1%5Y +0.1%
3.2B FY26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

No quarters filed for this figure.

Dividend per share

5Y CAGR −5.0%5Y CAGR −5.0%YoY +12.3%
$0.65 FY26— Q4 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q3 '20Q4 '20Q1 '21Q3 '21Q4 '21Q1 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q3 '24Q4 '24Q1 '25Q3 '25Q4 '25Q1 '26Q3 '26Q4 '26
Full TAK financials →

About Takeda Pharmaceutical ADR#

Data provided bySource: Twelve Data

Takeda Pharmaceutical Co Ltd ADR is a sponsored American depositary receipt representing shares of Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. Takeda develops, manufactures, markets, and out-licenses prescription medicines across major therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. Its portfolio is centered on specialty treatments and biologic medicines used in hospital, clinic, and outpatient settings, with commercial operations spanning Japan, the United States, Europe, and other international markets. The company also supports research and development, regulatory activities, and global manufacturing for small-molecule and biologic products. Takeda Pharmaceutical Co Ltd ADR provides U.S. investors with access to a diversified healthcare business focused on drug discovery, clinical development, and worldwide pharmaceutical commercialization.

Tokyo, Japan·49,281 employees·Drug Manufacturers - Specialty & Generic·takeda.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding TAK#

10 of the 193 ETFs ChartRow carries live hold TAK. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
EWJiShares MSCI Japan ETF1.1%
VPLVanguard FTSE Pacific ETF0.4%
VYMIVanguard International High Dividend Yield ETF0.3%
EFAiShares MSCI EAFE ETF0.2%
VEAVanguard FTSE Developed Markets ETF0.2%
VEUVanguard FTSE All-World ex-US ETF0.1%
VXUSVanguard Total International Stock ETF0.1%
URTHiShares MSCI World ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+23.75%+1.14%
JNJJohnson & Johnson+14.94%+0.79%
ABBVAbbVie Inc.+7.53%+0.20%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.86%+0.58%
MRKMerck & Co. Inc.+4.07%+0.55%
NVSNovartis AG+12.70%+0.16%
TMOThermo Fisher Scientific Inc.+5.61%+0.11%
AMGNAmgen Inc.+12.80%-0.30%